Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Scientists Combine Strategies to Mitigate CRISPR Off-Target Effects

NEW YORK (GenomeWeb) – In an effort to cut down on unintended consequences of CRISPR/Cas9 gene editing, scientists from Harvard Medical School have combined two strategies known to reduce off-target enzyme activity.

Led by Nicolas Wyvekens and Shengdar Tsai, the researchers looked at the effects of combining dimerizing RNA-guided Fok1-dCas9 fusion nucleases (RFNs) with truncated guide RNAs (tru-RNAs). They published their results yesterday in Human Gene Therapy.

Both RFNs and tru-gRNAs have been shown to increase specificity and decrease off-target effects. RFNs use a dead Cas9 (dCas9) to bind to the DNA but not to cut, using the Fok1 nuclease instead. However, Fok1 can edit only when it dimerizes; by designing guide RNAs that flank the cutting site towards each 5' end, the RFN complex achieves extra specificity. It must recruit two Fok1-dCas9s to enable cleavage at each target.

Tru-gRNAs have also been shown to reduce off-target editing while "generally maintaining" on-target activity, the authors wrote. They found that tru-gRNAs with 19 base pairs of complementarity to the target site, instead of the full 20, gave the best mix of decreased off-target and sustained on-target activity. They showed that 19-basepair gRNAs had about 90 percent of the on-target activity of full-length gRNAs.

The scientists showed that using both Fok1-dCas9 fusions and tru-gRNAS resulted in additive performance. They characterized off-target activity by using a deep sequencing method called GUIDE-Seq to find double-stranded breaks at off-target sites. GUIDE-Seq was developed by Tsai and Keith Joung, also a co-author on the Human Gene Therapy paper.

"On average, coexpression of FokI-dCas9 with tru-gRNAs as compared with conventional full-length gRNAs reduces unwanted indel mutation frequencies by 40 percent," the authors wrote, noting that there were still two sites where they saw off-target activity.

"Our data show that tru-RFNs provide a useful and further improved tool for high-precision genome editing applications in human cells," they wrote.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.